Description
AmbroSpray®-Innovative-The only Ambroxol in the form of oral spray
AmbroSpray® is indicated for the mucolytic treatment of acute and chronic bronchopulmonary diseases characterized by impaired mucous formation and transportation.
Produced in Italy
Current Registered in 10 European Countries
Including: Germany, Italy, Poland, Portugal, Bulgaria, Czech, Slovakia, Ukraine, Hungary
ü Accurate dose, convenient and fast administration
ü Reasonable 5% concentration, safe and effective
ü Easy to swallow, avoid choking risk
ü No need to wash the cup
ü No need for medical staff to assist in drug administration, greatly liberate the nursing staff
ü Bedridden patients do not need to get up to take the drug
Dosage: 13mL (50mg/mL)
Usage: 3 spray puffs each time (10mg/puff, 0.2ml), three times per day for adults and children over 6 years. This equals 30 mg ambroxol hydrochloride three times per day
- Pharmaceutical business
- global pharma business
Production Capacity:
Not informed
Delivery Timeframe:
Not informed
Incoterms:
EXW - Ex Works
Packaging Details:
Not informed
More about
GMep Medical Technology GmbH
10-50
Employees
Not informed
Not informed
Year
Established
Business type
- Industry / Manufacturer
- Importer / Trading Company
Keywords
- Pharmaceutical business
- global pharma business
Contact and location
- Haohan Qi
- +49 185 xxxxxxxx
- Düsseldor / North Rhine–Westphalia | Germany